Peptides for sexual function: a primer

If you have been searching for information about peptides and sexual function, most of what you will find online is either forum speculation or vendor marketing. This article covers what the clinical evidence actually shows, which candidates researchers associate with sexual function, and what you should understand before considering any of them. The short answer: one peptide, PT-141 (bremelanotide), has a real regulatory track record in this area. The rest of the conversation is largely preclinical or anecdotal.

This is not a dosing protocol. It is a map of the evidence.

What HSDD is and why it matters for this conversation

Most peptide research on sexual function targets a condition called hypoactive sexual desire disorder (HSDD), defined as persistently low sexual desire causing marked distress, in the absence of another medical, psychiatric, or relationship cause. HSDD affects a clinically significant portion of premenopausal women and is one of the few areas where a peptide has reached full regulatory approval. Understanding HSDD is useful because it is the lens through which the controlled trial data was collected^[1].

PT-141 (bremelanotide): the only peptide with an approval in this space

PT-141 is the research-programme code name for bremelanotide, a cyclic seven-amino-acid analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). The FDA approved it on 21 June 2019 under the brand name Vyleesi, for the treatment of acquired, generalised HSDD in premenopausal women^[2]. It is dosed as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity, with a limit of one dose per 24 hours and a recommended ceiling of eight doses per month. No equivalent authorisation exists from the EMA or the MHRA.

How it works

Unlike phosphodiesterase-5 inhibitors (the sildenafil class), which act peripherally on genital vasculature, bremelanotide works centrally. It is a non-selective agonist of the melanocortin receptor family, with its strongest activity at MC4R and MC3R, both expressed in hypothalamic and limbic brain regions involved in sexual desire and arousal^[2]. The downstream pharmacology is not fully mapped, but the MC4R pathway is thought to modulate dopaminergic and other circuits involved in sexual motivation. This central mechanism is the basis for its differentiated profile compared to topical or vascular treatments.

The pivotal evidence: RECONNECT phase 3

The approval rests on the RECONNECT programme: two identically designed randomised, double-blind, placebo-controlled trials (BMT-301 and BMT-302). Kingsberg and colleagues published the results in 2019^[1]. Approximately 1,247 premenopausal women with acquired, generalised HSDD self-administered 1.75 mg bremelanotide or placebo subcutaneously over a 24-week core period. The co-primary endpoints were change in the Female Sexual Function Index (FSFI) desire domain and change in a single-item sexual distress measure (FSDS-DAO item 13). Both trials met both endpoints versus placebo. Effect sizes were statistically significant but modest.

A 52-week open-label safety extension followed, showing no new safety signals over longer-term use^[3]. Prespecified subgroup analyses in 2022 confirmed that efficacy held across age, BMI, hormonal contraceptive use, and baseline testosterone quartile subgroups^[4].

The safety profile you need to know about

The Vyleesi prescribing information documents the key adverse events^[2]. Nausea is the dominant signal, occurring in roughly 40% of treated women, typically peaking within one hour and resolving within two hours. Flushing (approximately 20%), headache (approximately 11%), and injection-site reactions (approximately 13%) are also common. Transient blood-pressure elevation of about 6 mmHg systolic and 3 mmHg diastolic peaks 2 to 4 hours after dosing and resolves within 12 hours, which is why uncontrolled hypertension and known cardiovascular disease are explicit contraindications. Focal hyperpigmentation, a darkening of skin on the face, gums, or breasts, occurred in approximately 1% of patients at up to eight doses per month; the label notes that resolution was not confirmed in all patients.

What about use in men and off-label contexts?

A 2026 commentary in the Journal of Clinical Psychopharmacology by Pfaus and Balon examined whether bremelanotide should be considered for sexual arousal and desire disorders in men^[5]. The authors reviewed animal models showing MC4R activation increases appetitive sexual motivation and considered the early intranasal programme Palatin ran for male erectile dysfunction before the FDA halted it in 2007 over blood-pressure signals. Their conclusion is cautious: the mechanistic rationale exists, but there are no controlled human trials in men supporting a clinical recommendation. Off-label male use is common in community channels, but the evidence base for it consists of preclinical work and anecdote, not randomised trials.

A 2026 systematic review and meta-analysis by Toledo and colleagues examined treatment options for female sexual desire, arousal, and orgasmic dysfunctions across 36 studies^[6]. Bremelanotide was among the pharmacological options with evidence for improving desire and arousal dimensions of sexual response, alongside flibanserin and mindfulness-based cognitive behavioural therapy. The review underscored that direct comparative studies between pharmacological and psychological approaches are still absent from the literature.

What the evidence does not cover

Several gaps are worth naming. There is no controlled trial evidence for bremelanotide in postmenopausal women, in men with sexual-desire complaints, or for on-demand erectile-dysfunction use outside the halted intranasal programme. Long-term safety data beyond the open-label extension is thin. The mechanism by which central MC3/MC4 receptor activation drives changes in desire is partly understood but not at the level of detail of the dopamine or serotonin systems. Whether any sponsor will pursue an EMA or MHRA marketing authorisation is not currently known; no application has been publicly disclosed.

The regulatory picture outside the US

The EMA medicines register shows no marketing authorisation, EPAR, or referral for bremelanotide. The MHRA in the UK similarly has no authorised Vyleesi product. Lawful access in the EU, EEA, and UK therefore runs only through unlicensed-medicine or named-patient routes that a prescribing clinician requests and takes responsibility for. Grey-market sales of research-vial bremelanotide exist widely online. Those products carry none of the quality assurance of the regulated pharmaceutical. Per-country detail is on the PT-141 peptide page and the country-specific regulation hubs.

What to discuss with a clinician

If you are considering this area, the starting point is a clinical evaluation for HSDD itself, which has a defined diagnostic process, not a self-diagnosis from symptoms. In the United States, both bremelanotide (Vyleesi) and flibanserin (Addyi) are prescription-only options for premenopausal women with HSDD. See the PT-141 US regulation page for the full legal picture. In jurisdictions where no authorised product exists, a prescribing clinician can advise on unlicensed access if the indication is appropriate. Self-administering grey-market bremelanotide without clinical oversight, particularly if you have cardiovascular risk factors, sits outside what the safety evidence supports.

**Medical disclaimer:** This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.